Abstract
Introduction
More than a decade of translational research has been dedicated to developing a gene transfer regimen for sustained therapeutic expression of coagulation factor IX (F.IX) to correct the Xlinked bleeding disorder hemophilia B.
1 Two recent Phase I/II trials utilized in vivo adenoassociated viral (AAV) gene transfer to the liver. Preclinical studies in hemophilia B mice and dogs had demonstrated therapeutic multi-year expression following a single round of hepatic gene transfer. 1 Studies in non-human primates further supported the approach. 1,2 Additionally, the protocol resulted in induction of immune tolerance to F.IX in experimental animals, involving active suppression by regulatory T cells (Treg). [3] [4] [5] [6] [7] Nonetheless, AAV vectors are not invisible to the immune system. Their DNA genome and capsid structure is being sensed by TLR9 and TLR2, respectively, and humans often have pre-existing immunity. 8- 13 Activation of capsid-specific CD8 + T cells has now been observed in 4 clinical trials using AAV1, 2, or 8
vectors. 11, [14] [15] [16] [17] [18] These cytotoxic T lymphocytes (CTL) have the capacity to eliminate AAVtransduced cells resulting in loss therapeutic expression upon hepatic gene transfer.
The initial trial on AAV2-F.IX gene transfer to the liver uncovered two obstacles posed by capsid immunity; lack of hepatic transduction because of pre-existing neutralizing antibodies to the virus and activation of memory CD8 + T cells against capsid. 11, 15 Humans are naturally infected with AAVs, and there is high conservation and cross-reactivity of T cell epitopes among serotypes. 11, 16, 19, 20 Nonetheless, sustained therapeutic expression has now been achieved in six human subjects treated with varying doses of an AAV8 vector expressing F.IX from a hepatocyte-specific promoter. 18 However, 4 patients developed T cell responses against capsid, and two patients showed a rise in transaminases accompanied in one case by partial loss of F.IX Animal studies had not predicted such a response to input capsid. 21 In vitro studies have been helpful in studying T cell targeting of transduced human hepatocytes. 22, 23 However, development of a pre-clinical in vivo model of AAV vector immunogenicity has been frustrating and largely unsuccessful. Immunization against capsid by various methods designed to induce capsidspecific CD8 + T cells failed to eliminate transduced cells in mice, 20, [24] [25] [26] [27] [28] despite MHC class I (MHC I) presentation of capsid for several weeks following AAV gene transfer. 29 A more recent study showed some effect when a strong heterologous CD8 + T cell epitope was incorporated into the capsid. 30 Surprisingly, non-human primates, who are also natural hosts for AAVs, have also not been suitable models. This may be explained by several phenotypic differences between capsid-specific CTL in humans and non-human primates.
9,31
Our new study sought to establish a suitable murine model for pre-clinical testing of the effect of capsid-specific CD8 + T cells on therapeutic hepatocyte-derived F.IX expression and to identify immunologically stealthier capsid candidates. Following cellular entry, AAV capsid is phosphorylated, a signal for ubiquitination and subsequent proteosomal degradation.
32-34
Presentation of resulting peptides in the context of MHC I would be predicted to flag transduced hepatocytes for destruction by capsid-specific CD8 + T cells. 23 However, shunting of the capsid toward proteasomal degradation can be substantially reduced by elimination of potential phosphorylation sites through mutation of surface-exposed tyrosine residues to 
Methods
This study was approved under U Florida IACUC protocol #201003971.
AAV vectors
AAV vectors expressing human F.IX from the liver-specific ApoE enhancer/α 1 -antitrypsin promoter or a LacZ reporter gene packaged into AAV2, AAV2-Y444/500/730F [AAV2(Y-F)], or AAV8 capsids were as published. 15, 36 Vectors were administered at a dose of 1x10 11 vector genomes [vg]/mouse.
Generation of murine capsid-specific CD8 + T cells ("cap-CD8")
Male BALB/c mice (Jackson Lab, Bar Harbor, ME, 6 to 8 weeks old) were intramuscularly injected with AAV2-LacZ and boosted 7 days later with Previously, we found that a combination of 3 Y-F mutations at AAV2 capsid amino acid positions 444, 500, and 730 (referred to as AAV2(Y-F) capsid here) increased gene transfer to hepatocytes. 36 We hypothesized that hepatocytes transduced with this capsid variant may be less Thus far, studies in mice failed to demonstrate in vivo elimination of AAV transduced hepatocytes by capsid-specific CTL. 21 Interestingly, in models of colitis, aggressor cells are studied by adoptive transfer to recombinase activating gene deficient mice. 39 Therefore, we Administration of cap-CD8 substantially reduced systemic hF.IX expression from AAV2 vector (Fig. 1B) . Similar results were obtained when cap-CD8 treated mice were compared to mice that received control CD8 + T cells ("con-CD8", which were generated against an irrelevant influenza A virus epitope; Fig. 1D ). In either comparison, ~4-fold reduction in hF.IX levels was seen.
However, when cap-CD8 were given to AAV2(Y-F) transduced mice at different time points, only a minor decrease of ≤1.5-fold was observed, failing to reach statistical significance ( Fig   1E,F) . In order to provide optimal inflammatory signals that lead to up-regulation of MHC I expression, 40 a 3-day course of LPS administration was included, starting the day before cells were injected. This was not absolutely required, as Fig. 1C shows that a less substantial but still significant loss of AAV2-derived hF.IX expression was obtained even in the absence of LPS.
No loss of hF.IX expression was detected when cap-CD8 were given to mice 1 week after AAV2 gene transfer or later, indicating a difference between the murine model and humans (Fig. S2 ).
Cap-CD8 did not affect hF.IX expression from an adenoviral vector in mice, further confirming their specificity for AAV capsid (Fig. S3) .
To address the question of liver toxicity, ALT and AST levels were measured 7 days after T cell administration. Cap-CD8 induced a significant increase in systemic levels of both liver enzymes for AAV2 ( Fig. 2A) , which was not seen for AAV2(Y-F) transduced mice (Fig. 2B) .
Immunohistochemical analysis of liver sections from the same time point revealed CD8 + T cell infiltration in AAV2 transduced mice that had received cap-CD8 (Fig. 2C, upper When liver sections were stained for hF.IX one month after gene/T cell transfer, a 50% reduction in percent of hF.IX expressing hepatocytes was seen in AAV2-transduced recipients of cap-CD8 (Fig. 3A, C) . Importantly, no loss of hF.IX + hepatocytes was evident in mice that had received AAV2(Y-F) vector at various time points, and CD8 + T cell infiltrates were also not seen at this time point (Fig. 3B, D in vitro (Fig. 4D, E) . Similarly, Bortezomib prevented the loss of hF.IX expression from AAV2
1 1 vector upon cap-CD8 administration in vivo (Fig. 1D) . In AAV2(Y-F)-treated mice, Bortezomib treatment increased hF.IX levels even beyond those seen in the absence of cap-CD8 (Fig. 1E) .
Human hepatocytes transduced with AAV2(Y-F) present less capsid antigen and are more resistant to killing by capsid-specific CTL.
Choice of the VPQYGYLTL epitope allowed us to demonstrate relevance of our findings for MHC I presentation by human hepatocytes. 11, 19, 22 Comparison of the crystal structure of murine expresses luciferase in amounts proportional to the levels of antigen presentation. 22 Over a wide range of vector doses, AAV2(Y-F) vector yielded levels of capsid antigen presentation significantly lower than those measured on hepatocytes transduced with AAV2 vector at identical MOIs (Fig. 5A) . Quantitative real-time PCR to detect vector genome copy numbers confirmed that the difference in antigen presentation was not due to differences in cellular entry (data not shown).
To test whether the amounts of AAV capsid antigen being presented were sufficient to flag transduced cells for recognition and killing by CD8 + T cells, a CTL assay was performed as published. 23 Human hepatocytes were transduced overnight at varying MOIs followed by co- (Fig. 6B) . These results are in agreement with previously published work showing that tyrosine mutant AAV2 traffics more efficiently to the nucleus. applications, including current and future trials in hemophilia. 18, 43, 44 Poor in vitro transduction with AAV8 kept us from performing assays in hepatocyte cultures. However, since the dominant capsid epitopes for AAV2 and AAV8 are nearly identical and highly cross-reactive in BALB/c mice, 19 our in vivo model allowed us to test for the effect of a serotype switch. Upon administration of cap-CD8 at day 1 after AAV8 gene transfer, a 33% decrease in systemic expression and a significant reduction in hF.IX + hepatocytes (by ~ 27%) was observed (Fig. 7A,   B) . A similar result was obtained in a second experiment (Fig. 7C, D) . In contrast to AAV2, delayed administration of the cap-CD8 (on day 7 or day 14) had a substantial and even greater effect on hF.IX levels, resulting in a 3-to 5-fold loss of expression and a reduction in hF.IX + hepatocytes by up to 45% (Fig. 7C, D) . Also in contrast to AAV2, CD8 + T cell infiltrates were not seen at day 7 after T cell transfer but were prominent at later time points, regardless of the time point of T cell transfer (Figs. 7E and S7) . One of the T cell transfers resulted in a minor but statistically significant increase in liver enzymes at day 7 ( Fig. S8) , while the others did not (data not shown), suggesting that the time course of hepatotoxicity was altered as well.
Discussion

A novel murine model for targeting of AAV transduced liver by capsid-specific CTL.
Capsid-specific CD8 + T cells have been identified as a major hurdle and potential source of immunotoxicity in human recipients of AAV gene transfer. However, their ability to target AAV transduced human hepatocytes in vivo has been indirectly inferred from correlations between their emergence in peripheral blood and onset of transaminitis, 11, 18 while animal models failed to (Fig. S9 ) but, for unknown reasons, shows more similar hF.IX expression levels in the Rag-/-mice.
CTL-mediated killing is less efficient against hepatocytes transduced with Y-F capsid.
Using in vitro assays, hepatocytes transduced with AAV2 vectors were effectively killed by cap-CD8 over a wide range of vector doses, suggesting efficient MHC I presentation of input capsid, which is consistent with our prior studies. 23 Under conditions of limited phosphorylatation of Similarities and differences between humans and the murine model.
Similar to data in humans, our murine model exhibits targeting of AAV transduced liver by capsid-specific CTL, resulting in hepatotoxicity and loss of therapeutic expression. However, our data also indicate differences between humans and mice. The fact that we were not able to obtain loss of gene expression when CD8 + T cells were given 1 week or later after AAV2 gene transfer suggests that AAV2 capsid antigen presentation by murine hepatocytes is only sufficient for targeting by CTL in the first days after vector administration. Previous studies from our team demonstrated that epitopes displayed by AAV2 capsid can trigger proliferation of CD8 + T cells with corresponding receptors for several weeks following hepatic transfer of the vector. 29 It is
possible that cell lysis as tested here requires higher levels of surface expressed MHC I -peptide complexes compared to T cell proliferation as was tested in our previous studies. Nonetheless,
there is another interesting similarity between the mouse model and clinical studies. With the caveat that the number of vector-treated patients is small, responses to AAV2 occurred approximately 1 month after vector administration, while the response to AAV8 was markedly delayed to 8 to 10 weeks. 15, 18 Our novel mouse data support delayed and prolonged MHC I presentation of AAV8 capsid antigen in the liver (compared to AAV2), which allowed us to generate a time course of hF.IX expression more similar to what was observed in humans, i.e. an initial rise followed by a decline. Despite more rapid uncoating, 48 AAV8 capsid-derived peptides appear to be presented for an extended period of time. These results further support use of this particular murine model to study differences in capsid antigen presentation for alternate serotypes.
Implications for human gene therapy.
The impact of CD8 + T cell responses on AAV gene transfer to human liver is evident from the complete loss of hF.IX expression in a subject treated with AAV2. 15 Gene transfer in this patient had raised hF.IX levels from <1% to ~11% prior to transaminitis. Another subject recently treated with an AAV8 vector expressing hF.IX initially expressed levels of 6-8% of hF.IX, which declined to 2%. 18 Following the onset of transaminitis, the steroid drug prednisolone was given in an attempt to blunt the T cell response. Both patients had been treated with a vector dose of 2x10 12 vg/kg (similar to the 4x10 12 vg/kg used in our mouse studies). Clinical studies suggest that the risk of T cell responses and transaminitis is vector-dose dependent. 15, 17, 18 Therefore, development of capsid variants that have increased efficacy and reduced antigen presentation by hepatocytes is highly desirable. Our models would predict that AAV2(Y-F) vector minimize but not entirely eliminate the risk of CTL-mediated loss of transduced hepatocytes. Effectiveness of
the proteasome inhibitor indicates a residual level of proteasomal processing of AAV2(Y-F) capsid. Interestingly, the combination of AAV2(Y-F) vector and bortezomib yielded most optimal results for transgene expression (Figs. 1E, 4E, and S9A) . Contribution of other nonimmunoproteasomes in the cell (located in the cytoplasm or the nucleus) or other effects of proteasome inhibitors (such as generation of reactive oxygen species as discussed elsewhere) 22 may have also contributed to these findings.
Our study sheds light on findings from recent clinical results, 18 indicating that use of AAV serotype 8 alters the time frame but does not eliminate the risk of losing expression due to capsid-specific CTL, which needs to be considered for trial design. Finally, the model will be useful to design pharmacologic maneuvers that may reduce T cell activation, or reduce or alter processing and/or presentation of capsid-derived antigen. 
